C4 Therapeutics c4therapeutics.com


Public lists: Pharma Startups (6570)

C4 Therapeutics (NASDAQ: CCCC) advances a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of cells.

C4 Therapeutics (NASDAQ: CCCC) advances a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of cells.

Company (IPO / Went public)

Phone: 617-231-0700

Fax:

490 Arsenal Way
Suite 200
Watertown, 02472
Massachusetts, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
C4 Therapeutics $243M Oct 2, 2020

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related C4 Therapeutics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 25 investors
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Heterocyclic degronimers for target protein degradation May 11, 2020 Feb 02, 2021 Patent
C3-carbon linked glutarimide degronimers for target protein degradation Nov 09, 2018 Dec 01, 2020 Patent
Spirocyclic degronimers for target protein degradation Nov 09, 2018 May 26, 2020 Patent
Heterocyclic degronimers for target protein degradation Nov 09, 2018 May 12, 2020 Patent
Spirocyclic compounds Oct 16, 2020 Application
See all 14 patents